CJC-1295 and ipamorelin are two of the most heavily marketed compounds in the research-peptide market, typically sold together and framed as a 'stack' targeting the growth-hormone axis. Each has a specific pharmacological identity, and understanding the two separately is the starting point for reading either the primary literature or the marketing copy accurately.

What each compound is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates release of growth hormone (GH) from the anterior pituitary via the GHRH receptor.^[1] The 'CJC-1295' name has been used both for a version without a drug-affinity complex (DAC), which has a short half-life, and for a version with DAC, which has a substantially longer plasma half-life because it binds covalently to serum albumin. The two variants are not pharmacologically interchangeable and studies of one do not straightforwardly generalize to the other.

Ipamorelin is a selective ghrelin-mimetic — a small synthetic peptide that acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), the receptor for endogenous ghrelin.^[1] Its distinguishing pharmacological feature is relative selectivity for GH release without the same magnitude of effect on prolactin, cortisol, and ACTH that some other ghrelin-mimetics (GHRP-2, GHRP-6) show in comparable studies.

The rationale for combining them

The physiological rationale for combining a GHRH analog with a ghrelin-mimetic is that the two act at different receptors on the somatotroph, and in short-term pharmacodynamic studies their effects on GH release are approximately additive rather than redundant.^[1] This is a plausible mechanistic story, and the acute GH-response data are consistent with it. It is also the story that most 'stack' marketing rests on.

What the acute studies show

Single-dose and short-duration pharmacodynamic studies in humans have consistently shown that GHRH analogs and ghrelin-mimetics — including CJC-1295 variants and ipamorelin — can raise circulating GH concentrations and, over slightly longer time frames, downstream IGF-1.^[1] These are measurable biomarker changes. They confirm that the receptors are engaged and that the pituitary is responsive to the intervention.

A biomarker change is not, on its own, a clinical outcome. Regulators approve drugs on the basis of clinical outcomes — how patients feel, function, or survive — except in specific circumstances where a biomarker has been formally validated as a surrogate for those outcomes. GH pulse magnitude and IGF-1 concentration are physiologically meaningful measurements. They are not validated surrogates for the outcomes typically marketed to consumers.

Where the evidence stops

Whether raising GH pulses in otherwise-healthy adults, chronically, translates into the outcomes typically marketed — improved sleep architecture, faster injury recovery, meaningful changes in body composition, subjective 'anti-aging' effects — has not been established in adequately powered randomized trials for these specific compounds in this specific population.^[1] Some GH-related peptides have been studied in defined medical contexts (pediatric or adult growth hormone deficiency, HIV-associated wasting), where the underlying clinical picture and the risk-benefit calculation are very different from healthy-adult self-experimentation.

Regulatory and anti-doping posture

Neither CJC-1295 nor ipamorelin is an FDA-approved drug for any of the outcomes for which they are marketed in the research-peptide space. The World Anti-Doping Agency prohibits GHRH-releasing peptides and ghrelin-mimetics under section S2 of the Prohibited List (peptide hormones, growth factors, related substances, and mimetics).^[2] For anyone competing under a sport-governance body, the class is a straightforward rules violation regardless of intent. For the broader consumer, WADA classification is a data point about how the class is viewed by the institutions that spend the most resources evaluating it.

The 'CJC-1295 with DAC' complication

The two CJC-1295 variants — with and without DAC — differ substantially in half-life. The DAC version's covalent binding to serum albumin extends its effective duration, which changes the pattern of receptor stimulation from pulsatile toward sustained. The physiological consequences of sustained versus pulsatile GHRH-receptor activation are not identical, and the mismatch between the endogenous pattern (pulsatile) and a sustained pharmacological intervention is a legitimate object of inquiry, not a settled question.

Reading the pair

The honest summary is that CJC-1295 and ipamorelin have well-characterized short-term pharmacodynamic profiles and a much less well-characterized chronic clinical profile for the marketed use case. The gap between the acute biomarker literature and the outcome literature is where most of the confusion in this category lives, and it is the gap that a careful reader should hold in mind whenever a product description condenses the two into a single confident claim.